RT Journal Article
SR Electronic
T1 Impact of the Tier system on SARS-CoV-2 transmission in the UK between the first and second national lockdowns
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.23.21252277
DO 10.1101/2021.02.23.21252277
A1 Laydon, Daniel J
A1 Mishra, Swapnil
A1 Hinsley, Wes R
A1 Samartsidis, Pantelis
A1 Flaxman, Seth
A1 Gandy, Axel
A1 Ferguson, Neil M
A1 Bhatt, Samir
YR 2021
UL http://medrxiv.org/content/early/2021/02/24/2021.02.23.21252277.abstract
AB Objective Measure the effects of the Tier system on the COVID-19 pandemic in the UK between the first and second national lockdowns, before the emergence of the B.1.1.7 variant of concern.Design Modelling study combining estimates of the real-time reproduction number Rt (derived from UK case, death and serological survey data) with publicly available data on regional non-pharmaceutical interventions. We fit a Bayesian hierarchical model with latent factors using these quantities, to account for broader national trends in addition to subnational effects from Tiers.Setting The UK at Lower Tier Local Authority (LTLA) level.Primary and secondary outcome measures Reduction in real-time reproduction number Rt.Results Nationally, transmission increased between July and late September, regional differences notwithstanding. Immediately prior to the introduction of the tier system, Rt averaged 1.3 (0.9 – 1.6) across LTLAs, but declined to an average of 1.1 (0.86 – 1.42) two weeks later. Decline in transmission was not solely attributable to Tiers. Tier 1 had negligible effects. Tiers 2 and 3 respectively reduced transmission by 6% (5%-7%) and 23% (21%-25%). 93% of LTLAs would have begun to suppress their epidemics if every LTLA had gone into Tier 3 by the second national lockdown, whereas only 29% did so in reality.Conclusions The relatively small effect sizes found in this analysis demonstrate that interventions at least as stringent as Tier 3 are required to suppress transmission, especially considering more transmissible variants, at least until effective vaccination is widespread or much greater population immunity has amassed.Strengths and limitations of this studyFirst study to measure effects of UK Tier system for SARS-CoV-2 control at national and regional level.Model makes minimal assumptions and is primarily data driven.Insufficient statistical power to estimate effects of individual interventions that comprise Tiers, or their interaction.Estimates show that Tiers 1 and 2 are insufficient to suppress transmission, at least until widespread population immunity has amassed. Emergence of more transmissible variants of concern unfortunately supports this conclusion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDJL, NMF acknowledge funding from Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) grant, (ref. NIHR: PR-OD-1017-20002) from the National Institute for Health Research. SB acknowledges the NIHR BRC Imperial College NHS Trust Infection and COVID themes, the Academy of Medical Sciences Springboard award (ref. SBF004\1080). DJL, SM, WRH, NMF and SB are supported by Centre funding (grant MR/R015600/1) from the UK Medical Research Council under a concordat with the UK Department for International Development, the NIHR Health Protection Research Unit in Modelling Methodology and Community Jameel. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll model code and data sets are available from either the authors, or alternatively at https://github.com/ImperialCollegeLondon/covid19model. https://github.com/ImperialCollegeLondon/covid19model